Seroba Kernel
Press Archives
2009 Press Releases
2008 Press Releases
2007 Press Releases
2006 Press Releases
2005 Press Releases
2004 Press Releases
2002 Press Releases

2008 Press
11th November
Alimentary Health Ltd. Announces Licensing Agreement with P&G Pet Care.
5th November
Merrion Pharma signs License Agreement with Nova Nordisk up to US$58m
4th November
Merrion Pharma receives prestigious Frost & Sullivan Award
29th September
Merrion Pharma moves to next stage of drug research programme with Nova Nordisk
18th July
AGI announces agreement with FDA on key aspects of Rezular™ ARDIS Phase III programme
21st May
AGI Therapeutics reports key pharmacological and clinical findings for Rezular™ presented at DDW in San Diego
15th May
Opsona Therapeutics Ltd Receives Milestone Payments Under Wyeth Collaboration
14th May
Alimentary Health Ltd. receives orphan-drug designation for the treatment of pediatric ulcerative colitis
2nd April
AGI announces key findings of clinical PK study of arbaclofen (AGI-006)
17th March
AGI Therapeutics announces completion of the optimisation phase of development of AGI-010
21st February
Clinical study supports the pharmacokinetic and safety profile of Rezular™
5th February
BIOSENSIA COMPLETES A €2 MILLION FUNDING ROUND
5th February
AGI announces first patient dosed in Phase II trial of AGI-004 in chemotherapy-induced diarrhoea
27th January
Labcyte and Deerac Fluidics Combine Forces to Enhance Low Volume Liquid Handling
21st January
Alimentary Health Enters into Research and Development Agreement with ConvaTec
Alimentary Health Ltd. receives orphan-drug designation for the treatment of pediatric ulcerative colitis


Cork, Ireland, 14 May, 2008: Alimentary Health Ltd. (Alimentary Health), the development stage specialty biotechnology company, today announces that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA), has granted orphan-drug designation to Bifidobacterium infantis 35624 for the treatment of pediatric ulcerative colitis (UC). This new orphan-drug designation builds on the previously granted designation to Alimentary Health for pediatric Crohn’s Disease (CD). UC and CD account for the disorders that represent the inflammatory bowel diseases (IBDs). The pediatric population is defined as patients who are age sixteen or less.

Ulcerative colitis is a disease characterised by remitting and relapsing inflammation of the large intestine. For the treatment of UC, doctors typically prescribe medicines to reduce inflammation or as immunosuppressives. The disease usually requires these treatments to induce remission but surgery is also occasionally necessary. Paediatric onset leads to a lifelong debilitating disease with significant quality of life implications for UC patients and their families.

Barry Kiely, CEO of Alimentary Health, commented, "the achievement of orphan-drug designation for one of our probiotic technologies is an important step towards having probiotics serve as drug treatment for certain gastrointestinal and inflammatory conditions. This is and will continue to be a key goal of our research efforts."

Alimentary Health is a leader in pioneering the development of safe and effective therapeutics for Gastrointestinal (GI) and other indications.

Contact Information:

Financial Dynamics: Deborah Scott/John Dineen, Tel: +44 (0) 20 7269 7182

About Alimentary Health:

Alimentary Health is a development stage specialty biotechnology company located in Ireland. The company is focused on the discovery, development and commercialisation of proprietary probiotic and pharmabiotic treatments for gastrointestinal disorders and other inflammatory conditions. Alimentary Health is the foundation industry partner of the Alimentary Pharmabiotic Center based at University College Cork, Ireland.

www.alimentaryhealth.ie